Lytix strengthens the board with clinical development and commercial oncology experience
Edwin Klumper is a life science entrepreneur and combines a scientific and business background. At the general assembly in Lytix June 27th Dr Klumper was elected as a new board member, and he has just attended his first board meeting in Lytix.
Dr Klumper has an MD and a PhD in medicine from VU Academic Medical Center, Amsterdam and an MBA from Rotterdam School of Management, Netherlands. He is co-founder and CEO of iClusion Ltd (an internet platform company recruiting cancer patients for clinical studies), and co-founder and acting CMO of SMS-oncology Ltd (an oncology CRO). Prior he has served as acting CMO at several biotechnology companies, Vice-President Marketing & Sales Europe at Nabi Biopharmaceuticals, European Brand Director at Amgen, Business Unit Director at Amgen in The Netherlands and in the United Kingdom. Cancer research and development is his field of expertise. With 25 years of experience, he has been involved in the European launch of a block buster drug, has successfully turned around a company, and has supervised 80 cancer drug development programs and 20 clinical studies.